SCHEMBL21753348

SCHEMBL21753348

Cc1cc(CCl)ccc1-c1cccnc1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDO2 P48775 1/20 0.38
PPARG P37231 1/20 0.36
MKNK1 Q9BUB5 1/20 0.36
MKNK2 Q9HBH9 1/20 0.36
PIP4K2A P48426 1/20 0.34
PIP4K2C Q8TBX8 1/20 0.34
VHL P40337 1/20 0.34
PTGS1 P23219 1/20 0.34
PTGS2 P35354 1/20 0.34
AKT1 P31749 1/20 0.34
PDE3B Q13370 1/20 0.34
PDE3A Q14432 1/20 0.34
FABP1 P07148 1/20 0.34
CCR1 P32246 1/20 0.33
CCR8 P51685 1/20 0.33
PDE2A O00408 1/20 0.33
PDE10A Q9Y233 1/20 0.33
ELANE P08246 1/20 0.33
EIF4E P06730 1/20 0.33
PRMT5 O14744 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21753319 0.84 MKNK1 (0.42) TDO2PPARGMKNK1MKNK2PIP4K2A
SCHEMBL5492827 0.80 ESR1 (0.38) PTGS1PTGS2CYP2C19CA1CA2
SCHEMBL19932623 0.78 MKNK1 (0.53) TDO2PPARGMKNK1MKNK2VHL
SCHEMBL15730529 0.78 ALDH1A1 (0.44) TDO2MKNK1MKNK2PIP4K2APIP4K2C
SCHEMBL21753328 0.77 KDM4E (0.44) CCR1CCR8CYP1A2
SCHEMBL15730170 0.76 TDO2 (0.56) TDO2MKNK1MKNK2VHLAKT1
SCHEMBL19390554 0.75 ESR2 (0.50) TDO2MKNK1MKNK2PDE2APDE10A
SCHEMBL3421959 0.74 MKNK1 (0.52) TDO2MKNK1MKNK2VHLPTGS1
SCHEMBL31469002 0.74 MKNK1 (0.52) TDO2MKNK1MKNK2VHLPTGS1
SCHEMBL21753344 0.73 CYP17A1 (0.38) PPARGPDE3BPDE3APDE2APDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12016852-B2 Pyrrolidine glycosidase inhibitors ASCENEURON SA (CH) 2024-06-25 US disclosed
US-12016852-B2 Pyrrolidine glycosidase inhibitors ASCENEURON SA (CH) 2024-06-25 US disclosed
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2021-07-15 US disclosed
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2021-07-15 US disclosed
WO-2020039027-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON S. A. (CH) 2020-02-27 WO disclosed
WO-2020039027-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON S. A. (CH) 2020-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12016852-B2 Pyrrolidine glycosidase inhibitors PREP, GAA, DNPEP TDO2 2446/4885PPARG 3290/4885MKNK1 4094/4885
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS PREP, GAA, DNPEP TDO2 2160/4885PPARG 3413/4885MKNK1 4057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.